Option update 10-19-07: Baidu volatility Elevated at 90 into EPS

Posted Oct 19th 2007 8:45AM by Paul Foster
Filed under: Earnings Reports, Products and Services, Options

Baidu-(NASDAQ-BIDU), a Chinese language internet search provider, is recently up $4.00 to $324 in pre-open trading. The company will report earnings on 10/25. Smith Barney has a $250 price target. November option implied volatility of 89 is above its 26-week average of 56 according to Track Data, suggesting larger price fluctuations.

Vertex Pharma-(NASDAQ-VRTX), is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. The company sold off on 10/18/07 after promising trial data from Schering Plough's-(NYSE-SGP) Hepatitis C drug boceprevir was seen as a threat to VRTX's Telaprevir. Option volume was heavy on 54,154 contracts. November option implied volatility of 75 is above its 26-week average of 48 according to Track Data, suggesting larger price fluctuations.

Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Tags: Baidu, cancer, pain and bacterial infection, Cancer,PainAndBacterialInfection, Chinese language internet search provider, ChineseLanguageInternetSearchProvider, google ask yahoo msn aol, GoogleAskYahooMsnAol, inflammation, autoimmune diseases,, Inflammation,AutoimmuneDiseases,, option implied volatility, OptionImpliedVolatility, Schering Ploughs, ScheringPloughs, Telaprevir Hepatitis C drug boceprevir, TelaprevirHepatitisCDrugBoceprevir, Vertex Pharma, VertexPharma, viral diseases, inflammation, ViralDiseases,Inflammation